Search
West Pharmaceutical Services Inc
WSTAdd to Watchlist
327.950USD
+4.270+1.32%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
23.17BMarket Cap
43.62P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of West Pharmaceutical Services Inc is 8.33, ranking 52 out of 203 in the Healthcare Equipment & Supplies industry. The average price target is 350.00, with a high of 390.00 and a low of 285.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
356.264
Target Price
+8.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
117
Total
6
Median
9
Average
Company name
Ratings
Analysts
West Pharmaceutical Services Inc
WST
18
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
30
1
2
3
...
24
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is West Pharmaceutical Services Inc's expected revenue for the next quarter?
West Pharmaceutical Services Inc's expected revenue is 838.32M.
What is West Pharmaceutical Services Inc's price target?
Analysts forecast that West Pharmaceutical Services Inc's price target is USD 350.00, with the highest forecast at USD 390.00 and the lowest forecast at USD 285.00.
How have West Pharmaceutical Services IncWST's recent earnings per share performed?
The market expectation was USD 1.93, while West Pharmaceutical Services IncWST's earnings per share (EPS) for the previous quarter was USD 1.83. EPS for the next quarter is expected at USD 2.08.
What is the analyst rating for West Pharmaceutical Services Inc?
Based on the ratings of West Pharmaceutical Services Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
